Dare Bioscience, Inc.(DARE)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $10.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
DARE Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Dare Bioscience, Inc. (DARE), a Healthcare sector company. DARE is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $10.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Dare Bioscience, Inc. reports quarterly revenue of $152.5K, net income of $-3.0M, free cash flow of $-5.5M. Top institutional holders of DARE by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, GEODE CAPITAL MANAGEMENT,, US BANCORP \DE\, based on the most recent SEC filings. DARE trades on the Nasdaq exchange and files with the SEC under CIK 1401914. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DARE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Dare Bioscience, Inc. directly from SEC EDGAR.
Revenue
Q1 2026
$152.5K
Net Income
Q1 2026
$-3.0M
Free Cash Flow
Q1 2026
$-5.5M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
-99.9% YoYNet Income
+86.9% YoYOperating Income
+25.3% YoYEPS (Diluted)
-1458.4% YoYTotal Assets
-49.6% YoYTotal Debt
Op. Cash Flow
+130.3% YoY| Metric | FY 2024 | FY 2022 | FY 2021 | FY 2020 | FY 2018 | FY 2016 |
|---|---|---|---|---|---|---|
| Revenue | $9.8K -99.9% | $10.0M | $0.00 | — | — | $766.0K |
| Net Income | $-4.1M +86.9% | $-30.9M +20.0% | $-38.7M -41.2% | $-27.4M -63.7% | $-16.7M -2388.4% | $-672.7K |
| Operating Income | $-23.5M +25.3% | $-31.4M +19.7% | $-39.1M -42.6% | $-27.4M -62.3% | $-16.9M -2577.2% | $-630.6K |
| EPS (Diluted) | $-0.48 -1458.4% | $-0.03 +41.3% | $-0.05 +30.7% | $-0.08 | — | — |
| Total Assets | $22.1M -49.6% | $43.8M -21.5% | $55.8M +639.1% | $7.6M -3.5% | $7.8M +17444.7% | $44.6K |
| Total Debt | $4.1K | — | — | — | — | — |
| Operating Cash Flow | $5.5M +130.3% | $-18.1M +37.1% | $-28.8M -14.0% | $-25.2M -145.8% | $-10.3M | — |
Get alerted when DARE's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Dare Bioscience, Inc. including:
Top Institutional Holders of DARE
VANGUARD CAPITAL MANAGEMENT LLC
$841.4K462,305 shGEODE CAPITAL MANAGEMENT, LLC
$323.7K177,839 shUS BANCORP \DE\
$166.3K91,370 shVANGUARD FIDUCIARY TRUST CO
$120.0K65,938 shUBS Group AG
$78.9K43,363 shSTATE STREET CORP
$42.8K23,515 shXTX Topco Ltd
$40.7K22,339 shSUSQUEHANNA INTERNATIONAL GROUP, LLP
$31.2K17,130 shBlackRock, Inc.
$30.9K16,971 shNORTHERN TRUST CORP
$28.1K15,431 sh
| Fund | Value | Shares |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $841.4K | 462,305 |
| GEODE CAPITAL MANAGEMENT, LLC | $323.7K | 177,839 |
| US BANCORP \DE\ | $166.3K | 91,370 |
| VANGUARD FIDUCIARY TRUST CO | $120.0K | 65,938 |
| UBS Group AG | $78.9K | 43,363 |
| STATE STREET CORP | $42.8K | 23,515 |
| XTX Topco Ltd | $40.7K | 22,339 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $31.2K | 17,130 |
| BlackRock, Inc. | $30.9K | 16,971 |
| NORTHERN TRUST CORP | $28.1K | 15,431 |
More Healthcare Companies
View all Healthcare →Put DARE on your watchlist
Track score changes the day Dare Bioscience, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is DARE a good stock to buy?
13F Pro's AI-powered analysis of Dare Bioscience, Inc. (DARE) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for DARE are available on the DARE stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own DARE?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling DARE. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Dare Bioscience, Inc.'s investment landscape.